Overview

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Albuterol